Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Evgen upbeat on new data on potential breast cancer treatment

Mon, 14th Jun 2021 11:00

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced new preclinical data on Monday, which showed 'SFX-01' could be of benefit to metastatic breast cancer (mBC) patients who had become resistant to CDK4/6 inhibitors.
The AIM-traded firm said that, since the 'STEM' open-label phase 2 trial of SFX-01 in mBC concluded, CDK4/6 inhibitors had become standard-of-care as the first line mBC treatment for the large group of patients who were estrogen receptor positive.

Those drugs provided an extended period of progression-free survival, but invariably patients' tumours became resistant to them.

Options for such patients were limited, the company explained, especially since drugs used in such a setting were poorly tolerated.

As a result, Evgen's collaborators at the Manchester Breast Centre, the University of Manchester, were conducting further in-vitro preclinical work to assess the impact of SFX-01 in CDK4/6 resistance models.

An increasing body of in vitro data from there showed that in those models, SFX-01 could suppress tumour growth and metastasis in patients who had become resistant to CDK4/6 inhibitors.

In particular, SFX-01 reduced the viability and mammosphere colony formation ability of palbociclib-resistant cells in vitro.

Palbociclib was described by Evgen as the "leading" CDK4/6 inhibitor, marketed by Pfizer, with sales of around $5bn in 2019.

Mammospheres are colonies of primary tumour cells which represent a disease-relevant model to study drug effectiveness, it added.

Should that data be reinforced with in-vivo work, the company said it would pursue a phase 2 placebo-controlled study in second line estrogen receptor positive mBC treatment of patients who had failed on CDK4/6 inhibitors, which could begin in 2022.

The company said its previous open-label STEM trial in patients who had not received CDK4/6 inhibitors demonstrated evidence of anti-cancer activity via objective responses of tumour shrinkage.

It said 24% of patients showed a "durable clinical benefit" for at least six months, despite the late stage of disease and patients' established resistance to hormone therapy.

Of those, five patients were still receiving SFX-01 at 12 months, and one patient remained on SFX-01 treatment for 18 months.

Evgen said it also had a "mild and favourable" side effect profile for an anti-cancer drug.

"It is exciting that the preliminary data set generated by our colleagues at the Manchester Breast Centre suggests SFX-01 may have a valuable role in the treatment of patients who have developed CDK4/6 resistance patients," said chief executive officer Dr Huw Jones.

"We will soon be proceeding with the in vivo work and we are working up the design of the next trial."

At 1453 BST, shares in Evgen Pharma were down 4.73% at 8.05p.
More News
29 Oct 2009 12:05

London midday: Banks shine but Footsie falls

Shareholders in Royal Dutch Shell are grateful to Lloyds Banking Group for wresting investor attention away from the Anglo-Dutch company's poorly received results, as the part-nationalised bank confirmed it is contemplating digging an escape tunnel from the government's asset protection scheme. Llo

Read more
29 Oct 2009 08:23

Ebullient Evolution

Investment management firm Evolution Group expects to beat full year profit forecasts this year on the back of strong trading across all of its divisions. Revenues from the Investment Banking arm in the second half of 2009 will be at least double those seen in the first half, reflecting the increas

Read more
28 Aug 2009 16:40

London close: Comfortable gains posted

London's benchmark index finished the day with decent gains, though off earlier highs, with banks and miners proving the catalyst. Lloyds was the major riser on rumours that it is considering alternatives to the government's toxic asset protection scheme (APS), which could include the sale of Scot

Read more
28 Aug 2009 14:27

London afternoon: Shares aim higher

London's blue chips have added to gains in afternoon trading ahead of what is expected to be a rosy start on Wall Street. US stocks are seen posting good gains after Intel hiked its third-quarter revenue outlook just before the open. Kazakhmys, Xstrata, Rio Tinto, Antofagasta, Randgold Resources,

Read more
28 Aug 2009 11:33

London midday: Miners keep Footsie ahead

Miners and financials are giving the markets a cheer before the extended weekend break. Kazakhmys, Xstrata, Rio Tinto, Antofagasta, Randgold Resources, Anglo American and Vedanta Resources are all amongst the major risers. Lloyds is amongst the risers on rumours that it is considering alternative

Read more
28 Aug 2009 11:05

FTSE 250 movers: Restaurant Group leads risers

Restaurant Group is leading the FTSE 250 risers as cost control measures and a refusal to slash prices helped the company behind the Frankie & Bennie's and Chiquito chains to post a rise in profits for the first half of the year despite falling sales at its restaurants. Pre-tax profits climbed to

Read more
28 Aug 2009 09:45

Midcap round-up: JKX Oil, Melrose, SVG Capital, ...

Oil explorer JKX Oil saw the lower oil prices crimp profits for the half-year but said its second half performance is expected to be in line with expectations. Pre-tax profit slumped to £44.6m from £83.5m before revenues fell to $78.5m versus $116.8m in the same period last year. Revenues were wei

Read more
1 Jul 2009 12:35

Sector movers: M&S sales rise cheers retailers

Marks & Spencer is leading the retail sector higher after reporting a rise in sales over the first quarter. Total UK sales rose 1.7% over the period marking a further improvement in the trend seen over the last two quarters. General Merchandise rose 1.2% (Clothing +1.4%; Home +0.1%) and Food incre

Read more
1 Jul 2009 07:41

Evolution continues to perform well

Investment bank Evolution said it continues to perform well with the expansion of its institutional equities business proceeding according to plan. The group said its fixed income capabilities are also making good progress with continued growth in products and customers. Its private client business

Read more
20 May 2009 06:35

Wednesday tips round-up: Marks & Spencer, Burberry, Dairy Crest

The time to buy shares in M&S is when sales are rising, it has a long-term chief executive in place and there is a solid strategic plan for the future. Now is clearly not the time on any of those counts. Avoid says the Telegraph. Burberry, the luxury goods group, hailed its full-year numbers as a s

Read more
19 May 2009 16:31

London close: Miners and financials lead the way

Strength among financial plays and miners guaranteed London gains Tuesday, although it had looked a close call following a weak start on Wall Street. A near-13% slump in US housing starts in April proved a drag mid-afternoon before US stocks regained their poise and moved higher. Anglo American fi

Read more
19 May 2009 14:15

London afternoon: Shares off top after US housing starts shock

Alarming US housing starts data looks set to put the kybosh on the prospect of a firm start on Wall Street and has had a knock-on effect in London, where share prices are coming off the top. Marks & Spencer remains the day's biggest blue-chip faller after it saw a sharp drop in pre-tax profits to

Read more
19 May 2009 11:53

London midday: Equities advance on broad front

Risers outnumber fallers by about four to one among Footsie constituents as London's leading shares shrug off disappointing figures from Marks & Spencer to continue yesterday's advance. M&S is the day's biggest blue-chip faller after it saw a sharp drop in pre-tax profits to £706.2m from £1.13bn. I

Read more
19 May 2009 08:57

Fixed income revenues surge at Evolution

Stockbroker The Evolution Group is seeing very strong growth in its fixed income business while its institutional equities business has made encouraging progress this year. The group said it has continued to trade profitably in 2009 and develop in line with its plans. As well as adding 20 staff in

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.